A clinical trial to study the effects of fixed dose combination of Metoprolol and Telmisartan (Metosartan) in patients with essential hypertensio
- Conditions
- Health Condition 1: I10- Essential (primary) hypertension
- Registration Number
- CTRI/2022/09/045464
- Lead Sponsor
- Sun Pharma Laboratories Limited SP
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
• Male or female patients aged between 18 and 65 years (both inclusive) willing to provide written informed consent.
• Patients diagnosed with essential hypertension with co-existing stable ischemic heart disease [no change in severity of symptoms or nitrate
consumption in previous 3 months and defined as either stable symptoms (angina or dyspnea), which are thought to be related to chronic arterial disease (CAD), or asymptomatic patients with prior-diagnosed CAD].
• Patients with uncontrolled essential hypertension [having seated diastolic BP (SeDBP) 90 to 110 mmHg and/or seated systolic BP (SeSBP) 140 to 200 mmHg based on in-clinic blood pressure AND 24-hr average SBP = 130 and/or DBP = 80 mmHg based on ABPM], heart rate of >70 beats/minute and who is on stable dose of antihypertensive monotherapy for at least 4 weeks.
•Patients recommended FDC of Metoprolol succinate extended release + Telmisartan as part of physician’s clinical decision, in line with the prescribing information (PI) of Metosartan.
• Female subjects of childbearing potential must have a negative urine pregnancy test prior to study entry and must be willing to use acceptable method of contraception (female of childbearing potential is defined as one who has not been postmenopausal for at least one year, or has not been surgically sterilized, or has not had a hysterectomy at least three months prior to the start of this study. Acceptable method of contraception includes (e.g., barrier method with spermicide). The calendar method or usage of intra-uterine device (IUD) will not be considered as an acceptable method. The patient must be willing to practice recommended and acceptable method of contraception to prevent pregnancy from the time of study entry till 2 weeks post the last dose of study medication.
• Presence of any clinically relevant known comorbid conditions like hepatic impairment, chronic renal failure, thromboembolic disorders, cerebrovascular diseases, uncontrolled diabetes, uncontrolled thyroid disorder etc.
• Any known cardiac disease/disorder like severe bradycardia, heart block greater than first degree or significant first-degree block, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome without pacemaker etc. in which either Metoprolol or Telmisartan (individually or in combination) is contraindicated.
• Presence or history of secondary or malignant hypertension.
• Female subjects who are pregnant or lactating or are likely to become pregnant
• Patients receiving other beta blocker therapy (other than Metoprolol) in the last 4 weeks of treatment period prior to entering the study
• Any relevant clinical condition which, in the opinion of the investigator, could interfere with the outcome of the study.
• Patients expected to be non-compliant to the recommended instructions of the treating physician.
• Concomitant or prior (within 60 days of screening) use of any of the following medications: calcium channel blockers, digitalis glycosides, MAO inhibitors, fluoxetine, paroxetine, propafenone, quinidine, ACE inhibitors, clonidine, aliskiren.
• Patients who have participated in any study of an investigational product within last months.
• Subjects with known intolerance, hypersensitivity or any other contraindication to any of Metoprolol or Telmisartan.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method